Next-generation glioblastoma multiforme therapies based on multistage delivery nanovectors

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1112432

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $314,644.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nanomedicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer therapy | combination therapy | drug delivery systems | glioblastoma | targeted therapy

Related Links